A-dmDT390-bisFv(UCHT1) Fusion Protein in Combination With Ionizing Radiation for Treatment of Stage IV Melanoma

Phase 1/2 Terminated 2 enrolled Virogen Biotechnology Inc. University of Louisville · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this trial is to study A-dmDT390-bisFv(UCHT1) in combination with ionizing irradiation for the treatment of stage IV melanoma, a disease that is essentially incurable with median overall survival periods that range from 8-16 months.

Timeline

Start: 2014-02
Primary completion: 2020-12
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Resimmune®	Protein / enzyme biologic	—	—

A-dmDT390-bisFv(UCHT1) Fusion Protein in Combination With Ionizing Radiation for Treatment of Stage IV Melanoma

Summary

Timeline

Drugs

Indications